Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.72 USD | -0.79% | -2.29% | -3.72% |
Mar. 18 | Health Care Up as Traders Await Policy Statement -- Health Care Roundup | DJ |
Mar. 18 | Stocks downbeat before central bank rate storm | AN |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- The company is one of the best yield companies with high dividend expectations.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- One of the major weak points of the company is its financial situation.
- The company's enterprise value to sales, at 3.37 times its current sales, is high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.72% | 157B | C+ | ||
+30.83% | 687B | C+ | ||
+30.96% | 595B | B | ||
+0.01% | 378B | C+ | ||
+15.18% | 316B | C+ | ||
+11.39% | 308B | B- | ||
+0.78% | 211B | B- | ||
-6.09% | 208B | A+ | ||
-2.92% | 203B | B+ | ||
-5.94% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Pfizer, Inc. - Nyse
- Ratings Pfizer, Inc.